3 October, 2022

CAR-T Cells Production (Advanced Therapies)

FIRST CENTER IN SPAIN TO PRODUCE LENTIVIRUSES FOR CAR-T (CHIMERIC ANTIGEN RECEPTOR-T) CELLS IN CLINICAL TRIALS

Creatio has been the first center to produce lentiviruses for CAR-T (Chimeric Antigen Receptor-T) cells treatment in clinical trials in Spain. This new breed of treatment is currently revolutionizing the therapeutic approach for patients suffering from haematological pathologies such as leukaemia and lymphomas.

In 2017, Creatio began producing the first lentiviruses under GMP conditions for the Hospital Clínic in Barcelona, the first Spanish hospital to start clinical trials in this field of advanced therapies. Creatio is currently producing lentiviral particles that are distributed among 4 hospitals in Spain. Lentivirus is one of the essential starting materials to generate CAR-T cells as innovative drugs for patients suffering from haematological pathologies.

Creatio is committed to develop new therapies to improve the well-being of the population. Creatio gives support to leading researchers to develop new therapeutic strategies. Creatio brings knowledge and experience in the field of advanced therapies, facilitating the transfer of research projects into clinical-grade products for clinical trials in early stages.

The entire staff of Creatio is honoured to contribute with its knowledge, professionalism and work to the advancement of the ARI project (Assistance Intensive Research) to develop a cure for patients affected by haematological diseases. Creatio supports research groups so that more advanced therapies become a reality with the potential to cure disease that do not have a curative treatment yet.